Research programme: antibody-drug conjugate therapeutics - Celltrion

Drug Profile

Research programme: antibody-drug conjugate therapeutics - Celltrion

Alternative Names: CT P26

Latest Information Update: 17 Mar 2016

Price : $50

At a glance

  • Originator Celltrion
  • Class Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 01 Mar 2014 Preclinical trials in Breast cancer in South Korea (unspecified route) before March 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top